Synergistic PD-1/LAG-3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy

References

[1] S. F. Ngiow, S. Manne, Y. J. Huang, et al., “LAG-3 Sustains TOX Expression and Regulates the CD94/NKG2-Qa-1b Axis to Govern Exhausted CD8 T Cell NK Receptor Expression and Cytotoxicity,” Cell 187, no. 16 (2024): 4336-4354.

[2] L. P. Andrews, S. C. Butler, J. Cui, et al., “LAG-3 and PD-1 Synergize on CD8(+) T Cells to Drive T Cell Exhaustion and Hinder Autocrine IFN-γ-Dependent Anti-Tumor Immunity,” Cell 187, no. 16 (2024): 4355-4372.

[3] A. R. Cillo, C. Cardello, F. Shan, et al., “Blockade of LAG-3 and PD-1 Leads to Co-Expression of Cytotoxic and Exhaustion Gene Modules in CD8(+) T Cells to Promote Antitumor Immunity,” Cell 187, no. 16 (2024): 4373-4388.

[4] G. V. Long, E. J. Lipson, F. S. Hodi, et al., “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data,” Journal of Clinical Oncology 42, no. 33 (2024): Jco2401125.

[5] G. Chen, D. C. Sun, Y. Ba, et al., “Anti-LAG-3 Antibody LBL-007 Plus Anti-PD-1 Antibody Toripalimab in Advanced Nasopharyngeal Carcinoma and Other Solid Tumors: An Open-Label, Multicenter, Phase Ib/II Trial,” Journal of Hematology & Oncology 18, no. 1 (2025): 15.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.